BioSpace News Archive

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced results of the RELIANCE I study (REL-1017-301), evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder (MDD).

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 13,200 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

CPC (Colder Products Company), part of Dover (NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutical processing, today announced that its MicroCNX® Series Connectors were named a 2022 Pharma Innovation Award winner.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas.

Kewaunee Scientific Corporation announced results for its second quarter ended October 31, 2022.

Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable January 31, 2023 to shareholders of record at the close of business on December 30, 2022, representing an increase of 7.9% versus the prior year and previous quarter.

Ensysce Biosciences, Inc. today announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 5,800,000 shares.

Generate Biomedicines today announced that Jane Mendillo has been appointed to its board of directors.

Palisade Bio, Inc. announced that holders of 445,000 common stock purchase warrants, issued pursuant to the Company’s August 2022 public offering, have exercised such Warrants for cash.